Dissecting the role of HVEM and BTLA in constraining the germinal center B cell response
Dissecting the role of HVEM and BTLA in constraining the germinal center B cell response
批准号:
9327554
负责人:
Michelle Mintz
金额:
$3.55万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-01-01 至 2020-12-31
关键词:
AchievementAffinityAlpha CellAntibody AffinityAntigensB-Cell LymphomasB-Cell NonHodgkins LymphomaB-LymphocytesBindingBiologyCD4 Positive T LymphocytesCell CommunicationCellular biologyCuesDiffuseFollicular LymphomaGene TargetingGenerationsGrowthHelper-Inducer T-LymphocyteHumoral ImmunitiesITIMImmune responseImmunizeImmunoglobulin GenesImmunoglobulin Somatic HypermutationImmunoglobulinsImmunotherapyInterleukin-4KineticsLeadLigandsLymphoidMalignant - descriptorMemory B-LymphocyteMicroscopyMolecularMutateMutationOrganPTPN6 genePhosphoric Monoester HydrolasesPlasma CellsProcessProductionPublic HealthReactionRecruitment ActivityRoleSignal TransductionStructure of germinal center of lymph nodeT-LymphocyteTNFRSF1A geneTNFSF5 geneTestingVaccinesWorkantigen bindingcell growthexperimental studyherpesvirus entry mediatorhigh voltage electron microscopyimmunological synapseimprovedlarge cell Diffuse non-Hodgkin&aposs lymphomamembernovelnovel vaccinespathogenprotein functionreceptorresponsetwo-photonvaccine development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project summary/abstract
Germinal centers (GC) are regions in lymphoid organs where activated B cells are selected for their ability to
bind antigen with high affinity as well as generate memory B cells and high affinity antibodies. GC B cells have
the unique ability to improve their affinity to the immunizing antigen during an immune response through a
process of somatic hypermutation and selection. Although somatic hypermutation targets the immunoglobulin
genes, off-target mutations also occur and contribute to the malignant transformation of GC B cells into a subset
of non-Hodgkin B cell lymphomas. Our understanding of GC B cell biology has been greatly enriched by
understanding how such mutations over-ride the normal constraints to GC B cell growth. For instance, our lab
has shown S1PR2’s role in confining GC B cells to the GC and inhibiting growth by antagonizing Akt signaling.
HVEM, a TNF receptor superfamily member (also called TNFRSF14), is frequently mutated in germinal center
(GC) derived non-Hodgkin B cell lymphomas such as follicular lymphoma and diffuse large B cell lymphoma.
The mutations found in HVEM are predicted to lead to loss of the protein’s function, suggesting an important
growth regulatory role for HVEM in GC B cells. However, HVEM’s function in B cells has not been directly
examined. HVEM is highly expressed on follicular B cells and is expressed at a lower level on GC B cells,
possibly suggesting an advantage to more finely tuned signaling in the GC. In preliminary studies we have found
that deficiency in HVEM results in a cell intrinsic expansion of GC B cells. Of HVEM’s binding partners, the
immunoglobulin (Ig) superfamily co-inhibitory receptor B and T lymphocyte attenuator (BTLA) is most highly
expressed in the GC. BTLA is highly expressed on T follicular helper (Tfh) cells and BTLA deficiency in antigen-
specific CD4+ T cells increases IL-21 production and GC B cell expansion, suggesting a regulatory role of BTLA
on Tfh cells. Tfh cells have a crucial role in GC B cell selection and several molecular regulators have been
shown to tune the degree of T cell help provided to the GC B cell. We hypothesize that HVEM acts as a
suppressor of GC B cell responses through its interaction with BTLA, a potential negative regulator of B and T
cell engagement. Specifically, we aim to assess how HVEM regulates the magnitude of the GC B cell response
and if it impacts the induction of long-lived humoral immunity (1); and to examine if BTLA expression on T
follicular helper cells moderates the amount of T cell help during the GC reaction (2). This work will define a
novel negative regulator of the GC B cell response, which can lead to a rational target for vaccine development,
immunotherapy, and treatment for GC-derived B cell lymphomas.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金